Inhibition of the MCT1/4 or neutralization of lactate improves TME acidity, and preclinical studies have demonstrated that the MCT inhibitor AZD3965 in combination with a PD-L1 antibody significantly enhances T lymphocyte infiltration and inhibits tumor growth (173). Here, CD274 is linked to neoplasm.